Introduction
Depression is one of the major causes of ill health and economic burden worldwide. Antidepressant medication is a standard treatment and the first choice for depressed patients in current psychiatric guidelines. 1 Approximately 60% of patients respond well to active treatment, [2] [3] [4] but ~40%-50% of patients using the full dosage and duration of antidepressant medications still have residual symptoms and cannot obtain full remission. [4] [5] [6] One reason for this may be that some depressed patients discontinue treatment because of adverse effects or higher economic burden. 2 Moreover, misdiagnosis, genetic inheritance, and comorbid somatic disease also influence the outcome of treatment. 7, 8 In a 5-year follow-up study, Riihimäki et al 9 studied 137 major depressive disorders (MDDs) and found that the patients spent 34% of the follow-up time submit your manuscript | www.dovepress.com
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cai et al in major depressive episodes, 24% in partial remission, and 42% in full remission.
Szaulińska et al 10 reported that obstructive sleep apnea (OSA) is present in 11%-18% of patients with MDDs, 15%-48% of patients with schizophrenia, and 21%-43% of patients with bipolar disorder, but in only 5% of the general population. 11 One study has shown that patients diagnosed with OSA are at an increased risk of a diagnosis of depression. 12 Additionally, the symptoms of sleep apnea might imitate the symptoms of depression, including sleep disturbance, general fatigue, decreased volition and judgment ability, aggravated cognitive impairment, and a lower quality of life. 10 In addition, OSA might exacerbate symptom severity in MDDs. 8 Participants with both MDDs and OSA also reported more severe and longer episodes of depression. 13 Meanwhile, OSA might influence response to pharmacological treatment of depression as well as reduce patient adherence to antidepressants. 8, 14 Waterman et al 14 studied 400 patients with MDDs and found that those with comorbid OSA were 1.5 times less likely to respond to 12 weeks of treatment with the antidepressant venlafaxine than those with either depressive disorder occurring alone. Kerner et al 15 confirmed that the cognitive performance of MDDs comorbid with severe OSA is even worse than that of mild to moderate OSA, while some reports suggest that depressive symptoms might be improved in at least some patients receiving continuous positive airway pressure therapy or other treatment for OSA. [16] [17] [18] [19] From the point of view of the physicians, this suggests that screening and treatment for OSA is very important. 10 In depressive disorders, comorbid OSA is even higher. 10 Physicians should consider screening for OSA when assessing patients for depression, as it may indicate more difficulty to treat depression. 8, 19 However, it is difficult to define who actually is at risk of OSA in depressive disorders. This has prompted the need to identify OSA using appropriate risk factors in clinical settings. Multiple studies have found that sex, age, obesity, snoring, pharyngeal abnormalities, and cephalometric features are risk factors for OSA in the general population. [20] [21] [22] Hattori et al 23 studied 32 mood disorder patients and found that appropriate OSA risk factors (such as apnea, snoring, and body mass index [BMI]) may help to better identify OSA. 23 Nonetheless, to our knowledge, there have been few studies on risk factors for OSA in depressive disorders. We screened OSA patients with mood disorders presenting with depression using polysomnography (PSG) and examined which or how many risk factors would contribute most to OSA screening.
Methods Participants
All participants provided written informed consent to be included in the study, and the study design was approved by the ethics committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. We reviewed 1,091 medical files of patients who had undergone in-room PSG from December 2013 to December 2015. The inclusion criteria were as follows: 1) diagnosis of an MDD or a bipolar disorder (in a major depressive episode) through a structured MiniInternational Neuropsychiatric Interview (MINI) based on the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV); 2) patients aged 18 years or older; and 3) the Hamilton Depression Rating Scale (HAMD; 17 items) $10. Patients with BMI $30 kg/m 2 , underlying respiratory disease, history of taking drugs that can affect normal sleep architecture and psychotic symptoms, suicidal thoughts, restless legs syndrome, diagnosis of other sleep-related disorder, other clinical phases of bipolar disorder, and a previous history of treatment for OSA were excluded. Patients with mood disorder who had undergone no pharmacological therapy were also excluded. A total of 115 patients met the criteria and were divided into non-OSA (n=56) and OSA (n=59) groups according to PSG results. Patients who had apnea-hypopnea index (AHI) ,5 were defined as the non-OSA group, whereas the OSA group was defined as those with an AHI $5.
Polysomnography
PSG recording was performed using Trackit 32/0 (Lifelines Ltd, Hants, UK). Electroencephalography, electrocardiogram, and electromyography of chin and leg; arterial oxygen saturation (SaO 2 ); airflow at nose and mouth; chest and abdominal movement; and body position were recorded. Measurements were made from 21.00 hours to 06.00 hours the following morning in a quiet room. Apnea events were defined as complete cessation or near-complete cessation of airflow for $10 seconds, and hypopnea events were based on a 30% reduction of airflow for 10 seconds accompanied by SaO 2 reduction of .3%. The number of episodes of apnea and hypopnea per hour during total sleep time was calculated, and the result was the AHI.
assessment
The HAMD, the Hamilton Anxiety Rating Scale (HAMA), and the Pittsburgh Sleep Quality Index (PSQI) were used for included patients when they underwent PSG. 
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Osa and depressive disorders bipolar disorder]), and AHI, logistic regression was used. All statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA), and P,0.05 was considered as statistically significant.
Results
The mean age of the patients was 51.58±11.48 years. Seventyfour patients were diagnosed with MDD, and 41 were diagnosed with bipolar affective disorder. Their mean HAMD score was 20.97±4.47 for 17 items. On PSG, 59 patients were diagnosed with OSA (AHI $5) and 56 patients were diagnosed with non-OSA (AHI ,5; Table 1 ).
When referring to the correlation between risk factors and AHI, the results showed a significant association between the AHI and diagnosis (MDD or bipolar disorder [in a major depressive episode]), BMI, HAMD, and PSQI (Table 2) .
Discussion
In all, 15%-30% of patients with depressive disorder were classified as having treatment-resistant depression. 23 A previous study reported that OSA is present in 11%-18% of patients with MDDs. 10 From this, it is reasonable to assume that some treatment-resistant depression is comorbid with OSA. 24 However, of the 115 depressive disorder patients who met the inclusion criteria in the present study, 51.3% had OSA. Additionally, in the logistic regression analysis, the results showed a higher significant relation between AHI and diagnosis (MDDs or bipolar disorder [in a major depressive episode]), BMI, HAMD, and PSQI. Therefore, we may consider that there were many undiagnosed OSA cases in depression patients.
Of the 115 patients in the present study, 41 were diagnosed with bipolar depression and 74 were diagnosed with unipolar depression. Of the 59 depressive disorder patients who met the OSA criteria, 16 were diagnosed with bipolar depressive disorder and 43 were diagnosed with unipolar depression. Meanwhile, the logistic test results showed that the risk of comorbid OSA in unipolar depression is 2.72 times that of bipolar depressive disorders. It is thought that the OSA diagnosis rate in MDD patients is higher than that in bipolar disorder patients, and the possibility cannot be ruled out that the sample included a high proportion of patients with MDD. Furthermore, a significant correlation was seen between the HAMD and PSQI scores and the AHI or OSA diagnosis. Thus, it seems that having a higher HAMD or PSQI score is associated with increased probability or possibility of having OSA. A significant correlation was seen between AHI and depressive severity, as well as sleep quality, according to HAMD and PSQI scores in the present patients.
Some studies have indicated that risk factors for OSA include sex, age, obesity, pharyngeal abnormalities, and cephalometric features. [20] [21] [22] 25 In our results, significant associations were noted between the BMI and AHI or OSA diagnosis. It would be logical to assume that a higher BMI is associated with increased probability or possibility of having OSA. Therefore, it may be concluded that these risk factors (BMI, HAMD, PSQI, and diagnosis) would greatly increase the diagnosis rate of OSA in the psychiatric department. Depressed patients with the above risk factors or suspected OSA should be referred to a sleep disorder center for evaluation by PSG to confirm the diagnosis of OSA.
The limitations of our study design should also be noted. The symptom of daytime sleepiness was related to the severity of OSA. However, others found the predictive value of excessive daytime sleepiness for OSA to be low. 21, 25 In addition, Rosenthal and Dolan 25 found that nonspecific daytime sleepiness may be more strongly observed in mood disorder patients than in the general population because of psychotropic drugs or the underlying disease itself. Clinical factors, such as cardiovascular disease, hypertension, and diabetes, have been shown to be associated with OSA. 13 However, the sample size was relatively small in the present study. In the future, investigations with a larger sample 14 Psychiatrists involved in treating mood disorders comorbid with OSA should be cautious in using drugs with a muscle relaxant effect such as benzodiazepines.
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